版本:
中国

BRIEF-Teva collaborates with Intel to develop a device for use in huntington disease

Sept 15 Teva Pharmaceutical Ltd Says It Will Deploy The Technology Platform In A Sub

* Teva Pharmaceutical announces collaboration with Intel Corp to develop a unique wearable device and machine learning platform for use in huntington disease

* Study within ongoing Phase 2 Open-Pride HD study

* Says study will start towards end of year and will take place in centers in U.S and Canada Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐